1
|
Richards K, Johnsrud M, Zacker C, Sasané R. Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation. Community Ment Health J 2024:10.1007/s10597-024-01347-7. [PMID: 39240484 DOI: 10.1007/s10597-024-01347-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 08/18/2024] [Indexed: 09/07/2024]
Abstract
Researchers have used elements of administrative healthcare claims data (e.g., diagnosis codes and medications) to calculate rates of extrapyramidal symptoms (EPS) in patients with schizophrenia who utilize second-generation antipsychotics (SGAs). However, a detailed description of claims-based EPS evidence has not been previously provided, which is the objective of the current study. This descriptive study, using 2016-2020 de-identified multi-state Medicaid administrative claims data, followed patients diagnosed with schizophrenia for 12 months after initiation of SGA therapy to identify and describe the first evidence of EPS. Time to EPS evidence was calculated and continuously-eligible patients were followed for an additional 12 months to examine EPS medication utilization and costs. Following SGA initiation, 13.6% (n = 2,288) of patients had evidence of EPS during the 12-month follow-up period. Mean time to first evidence of EPS after SGA initiation was 103.7 days (sd = 112.2, median = 58). For a majority of patients (n = 1,636, 71.5%), an EPS medication claim was the initial evidence of EPS, rather than an EPS diagnostic claim. Additionally, a quarter of patients (25.3%) in the EPS evidence cohort had a claim for an EPS medication on the same date as SGA initiation, possibly indicating prophylactic prescribing to prevent EPS development. Nearly 93% of those with EPS medication claims were treated with benztropine, while less than 2% received deutetrabenazine or valbenazine (indicated for tardive dyskinesia (TD)). Annual per patient EPS medication expenditures were $804 (sd = 7,080) overall, but only $40 (sd = 104) when excluding the higher-cost TD medications. Nearly 14% of Medicaid patients with schizophrenia who initiated SGA treatment had evidence of EPS based on claims data. The majority of the time, this evidence was derived from a prescription claim for a medication to treat EPS, rather than an EPS diagnostic claim. Prophylactic prescribing for EPS occurred more often than expected and should be explored more fully. While the cost of traditional EPS medications minimally contributes to the overall cost of care in schizophrenia, use of newer TD drugs can substantially increase spending.
Collapse
Affiliation(s)
- Kristin Richards
- TxCORE (Texas Center for Health Outcomes Research and Education), College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1930, Austin, TX, 78712, USA.
| | - Michael Johnsrud
- TxCORE (Texas Center for Health Outcomes Research and Education), College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1930, Austin, TX, 78712, USA
| | | | | |
Collapse
|
2
|
Foucher JR, Hirjak D, Walther S, Dormegny-Jeanjean LC, Humbert I, Mainberger O, de Billy CC, Schorr B, Vercueil L, Rogers J, Ungvari G, Waddington J, Berna F. From one to many: Hypertonia in schizophrenia spectrum psychosis an integrative review and adversarial collaboration report. Schizophr Res 2024; 263:66-81. [PMID: 37059654 DOI: 10.1016/j.schres.2023.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 03/14/2023] [Accepted: 03/15/2023] [Indexed: 04/16/2023]
Abstract
Different types of resistance to passive movement, i.e. hypertonia, were described in schizophrenia spectrum disorders (SSD) long before the introduction of antipsychotics. While these have been rediscovered in antipsychotic-naïve patients and their non-affected relatives, the existence of intrinsic hypertonia vs drug-induced parkinsonism (DIP) in treated SSD remains controversial. This integrative review seeks to develop a commonly accepted framework to specify the putative clinical phenomena, highlight conflicting issues and discuss ways to challenge each hypothesis and model through adversarial collaboration. The authors agreed on a common framework inspired from systems neuroscience. Specification of DIP, locomotor paratonia (LMP) and psychomotor paratonia (PMP) identified points of disagreement. Some viewed parkinsonian rigidity to be sufficient for diagnosing DIP, while others viewed DIP as a syndrome that should include bradykinesia. Sensitivity of DIP to anticholinergic drugs and the nature of LPM and PMP were the most debated issues. It was agreed that treated SSD should be investigated first. Clinical features of the phenomena at issue could be confirmed by torque, EMG and joint angle measures that could help in challenging the selectivity of DIP to anticholinergics. LMP was modeled as the release of the reticular formation from the control of the supplementary motor area (SMA), which could be challenged by the tonic vibration reflex or acoustic startle. PMP was modeled as the release of primary motor cortex from the control of the SMA and may be informed by subclinical echopraxia. If these challenges are not met, this would put new constraints on the models and have clinical and therapeutic implications.
Collapse
Affiliation(s)
- Jack R Foucher
- ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU.
| | - Dusan Hirjak
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, EU
| | - Sebastian Walther
- Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland
| | - Ludovic C Dormegny-Jeanjean
- ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU
| | - Ilia Humbert
- CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU
| | - Olivier Mainberger
- ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU
| | - Clément C de Billy
- ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU
| | - Benoit Schorr
- Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France, EU; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, FMTS, University of Strasbourg, France, EU
| | - Laurent Vercueil
- Unité de neurophysiologie clinique, CHU Grenoble Alpes, Université Grenoble Alpes, France, EU; INSERM U1216, Institut de neurosciences, Grenoble, France, EU
| | - Jonathan Rogers
- Division of Psychiatry, University College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK
| | - Gabor Ungvari
- Section of Psychiatry, School of Medicine, University Notre Dame Australia, Fremantle, Australia
| | - John Waddington
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland, EU
| | - Fabrice Berna
- Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France, EU; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, FMTS, University of Strasbourg, France, EU
| |
Collapse
|
3
|
Singh G, Magny S, Singh H, Singh S, Virk IS. Differentiating Between Lithium Tremors and Extrapyramidal Tremors in a Patient on Long-Term Antipsychotics and Lithium Medication. Cureus 2023; 15:e42406. [PMID: 37637665 PMCID: PMC10447632 DOI: 10.7759/cureus.42406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/24/2023] [Indexed: 08/29/2023] Open
Abstract
Tremors are characterized by involuntary rhythmic shaking movement in different regions of the body. Tremors can manifest in various forms and have various causes, including the use of drugs such as lithium and antipsychotic medication. In a clinical setting, it is vital to understand the varieties of tremors presented and administer the appropriate pharmacotherapy needed. We present a case of a patient that has been experiencing fine tremors while on antipsychotics and lithium medication for the past year. We address differentiating the tremors while proposing managing the effects based on their mechanisms of action.
Collapse
Affiliation(s)
- Gurraj Singh
- Psychiatry, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, IND
| | - Sherlyne Magny
- Medicine, American University of Integrative Sciences School of Medicine, Bridgetown, BRB
| | - Harsehaj Singh
- Psychiatry, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, IND
| | - Sukhnoor Singh
- Psychiatry, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, IND
| | - Inderpreet S Virk
- Psychiatry, California Department of Corrections and Rehabilitation, Vacaville, USA
| |
Collapse
|
4
|
M Elsharkawy F, M Amin M, A Shamsel-Din H, Ibrahim W, Ibrahim AB, Sayed S. Self-Assembling Lecithin-Based Mixed Polymeric Micelles for Nose to Brain Delivery of Clozapine: In-vivo Assessment of Drug Efficacy via Radiobiological Evaluation. Int J Nanomedicine 2023; 18:1577-1595. [PMID: 37007986 PMCID: PMC10065422 DOI: 10.2147/ijn.s403707] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 03/14/2023] [Indexed: 03/28/2023] Open
Abstract
Purpose The research objective is to design intranasal brain targeted CLZ loaded lecithin based polymeric micelles (CLZ- LbPM) aiming to improve central systemic CLZ bioavailability. Methods In our study, intranasal CLZ loaded lecithin based polymeric micelles (CLZ- LbPM) were formulated using soya phosphatidyl choline (SPC) and sodium deoxycholate (SDC) with different CLZ:SPC:SDC ratios via thin film hydration technique aiming to enhance drug solubility, bioavailability and nose to brain targeting efficiency. Optimization of the prepared CLZ-LbPM using Design-Expert® software was achieved showing that M6 which composed of (CLZ:SPC: SDC) in respective ratios of 1:3:10 was selected as the optimized formula. The optimized formula was subjected to further evaluation tests as, Differential Scanning Calorimetry (DSC), TEM, in vitro release profile, ex vivo intranasal permeation and in vivo biodistribution. Results The optimized formula with the highest desirability exhibiting (0.845), small particle size (12.23±4.76 nm), Zeta potential of (-38 mV), percent entrapment efficiency of > 90% and percent drug loading of 6.47%. Ex vivo permeation test showed flux value of 27 μg/cm².h and the enhancement ratio was about 3 when compared to the drug suspension, without any histological alteration. The radioiodinated clozapine ([131I] iodo-CLZ) and radioiodinated optimized formula ([131I] iodo-CLZ-LbPM) were formulated in an excellent radioiodination yield more than 95%. In vivo biodistribution studies of [131I] iodo-CLZ-LbPM showed higher brain uptake (7.8%± 0.1%ID/g) for intranasal administration with rapid onset of action (at 0.25 h) than the intravenous formula. Its pharmacokinetic behavior showed relative bioavailability, direct transport percentage from nose to brain and drug targeting efficiency of 170.59%, 83.42% and 117% respectively. Conclusion The intranasal self-assembling lecithin based mixed polymeric micelles could be an encouraging way for CLZ brain targeting.
Collapse
Affiliation(s)
- Fatma M Elsharkawy
- Regulatory Affairs Department, Al Andalous for Pharmaceutical Industries, Giza, Egypt
| | - Maha M Amin
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Hesham A Shamsel-Din
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Walaa Ibrahim
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Ahmed B Ibrahim
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Sinar Sayed
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
- Correspondence: Sinar Sayed, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, 11562, Egypt, Tel +2 01010421543, Email
| |
Collapse
|
5
|
Pandey S, Pitakpatapee Y, Saengphatrachai W, Chouksey A, Tripathi M, Srivanitchapoom P. Drug-Induced Movement Disorders. Semin Neurol 2023; 43:35-47. [PMID: 36828011 DOI: 10.1055/s-0043-1763510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
Drug-induced movement disorders (DIMDs) are most commonly associated with typical and atypical antipsychotics. However, other drugs such as antidepressants, antihistamines, antiepileptics, antiarrhythmics, and gastrointestinal drugs can also cause abnormal involuntary movements. Different types of movement disorders can also occur because of adverse drug reactions. Therefore, the important key to diagnosing DIMDs is a causal relationship between potential offending drugs and the occurrence of abnormal movements. The pathophysiology of DIMDs is not clearly understood; however, many cases of DIMDs are thought to exert adverse mechanisms of action in the basal ganglia. The treatment of some DIMDs is quite challenging, and removing the offending drugs may not be possible in some conditions such as withdrawing antipsychotics in the patient with partially or uncontrollable neuropsychiatric conditions. Future research is needed to understand the mechanism of DIMDs and the development of drugs with better side-effect profiles. This article reviews the phenomenology, diagnostic criteria, pathophysiology, and management of DIMDs.
Collapse
Affiliation(s)
- Sanjay Pandey
- Department of Neurology, Amrita Hospital, Faridabad, Delhi National Capital Region, India
| | - Yuvadee Pitakpatapee
- Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
| | - Weerawat Saengphatrachai
- Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
| | - Anjali Chouksey
- Department of Neurology, Shri Narayani Hospital and Research Centre, Vellore, Tamil Nadu, India
| | - Madhavi Tripathi
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Prachaya Srivanitchapoom
- Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
| |
Collapse
|
6
|
Abstract
Mirtazapine has often been prescribed as add-on treatment for schizophrenia in patients with suboptimal response to conventional treatments. In this review, we evaluate the existing evidence for efficacy and effectiveness of add-on mirtazapine in schizophrenia and reappraise the practical and theoretical aspects of mirtazapine-antipsychotic combinations. In randomized controlled trials (RCTs), mirtazapine demonstrated favourable effects on negative and cognitive (although plausibly not depressive) symptoms, with no risk of psychotic exacerbation. Mirtazapine also may have a desirable effect on antipsychotic-induced sexual dysfunction, but seems not to alleviate extrapyramidal symptoms, at least if combined with second-generation antipsychotics. It is noteworthy that all published RCTs have been underpowered and relatively short in duration. In the only large pragmatic effectiveness study that provided analyses by add-on antidepressant, only mirtazapine was associated with both decreased rate of hospital admissions and number of in-patient days. Mirtazapine hardly affects the pharmacokinetics of antipsychotics. However, possible pharmacodynamic interactions (sedation and metabolic offence) should be borne in mind. The observed desired clinical effects of mirtazapine may be due to its specific receptor-blocking properties. Alternative theoretical explanations include its possible neuroprotective effect. Further well-designed RCTs and real-world effectiveness studies are needed to determine whether add-on mirtazapine should be recommended for difficult-to-treat schizophrenia.
Collapse
|